# Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

> **NCT02349503** · PHASE1 · WITHDRAWN · sponsor: **Neurocrine Biosciences**

## Conditions studied

- Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** NBI-77860
- **DRUG:** NBI-77860
- **DRUG:** NBI-77860

## Key facts

- **NCT ID:** NCT02349503
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-02
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349503, "Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02349503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*